Targeting lymphocyte activation to treat rheumatoid arthritis

Joint Bone Spine

Volumn 76, Issue 4, 2009, Pages 327-332

  Falgarone, Géraldine ^a,b   Semerano, Luca ^a,b   Rullé, Sandrine ^a   Boissier, Marie Christophe ^a,b  

^a UNIVERSITÉ PARIS 13   (France)

^b AVICENNE HOSPITAL   (France)

Author keywords

Abatacept; Rheumatoid arthritis; T cell antigen presenting cell interactions

Indexed keywords

ABATACEPT; AUTOANTIGEN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; PNEUMOCOCCUS VACCINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TETANUS TOXOID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADD ON THERAPY; ANTIGEN PRESENTING CELL; ARTHRITIS; AUTOIMMUNITY; BIOLOGICAL THERAPY; BREAST CANCER; CELL INTERACTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; CLINICAL TRIAL; COLORECTAL CANCER; DENDRITIC CELL; DISABILITY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HEMATOPOIETIC CELL; HUMAN; IN VIVO STUDY; INFECTION; JOINT INJURY; LUNG CANCER; LYMPHOCYTE; MUSCULOSKELETAL PAIN; NAUSEA AND VOMITING; NONHUMAN; OPTIMAL DRUG DOSE; PAIN; PATIENT SATISFACTION; POPULATION; QUALITY OF LIFE; REMISSION; RHEUMATIC SYNOVITIS; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY; SUPPRESSOR CELL; SYNOVITIS; SYSTEMATIC REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT FAILURE; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOIMMUNITY; CELL COMMUNICATION; HUMANS; IMMUNOCONJUGATES; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES;

EID: 67649973605     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2008.12.007     Document Type: Short Survey

References (40)

1. Firestein G.S., and Zvaifler N.J. How important are T cells in chronic rheumatoid synovitis?. Arthritis Rheum 33 (1990) 768-773
2. Firestein G.S., and Zvaifler N.J. How important are T cells in chronic rheumatoid synovitis?: II. T cell-independent mechanisms from beginning to end. Arthritis Rheum 46 (2002) 298-308
3. - memory T cells in the peripheral blood, synovial fluid, and synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum 39 (1996) 844-854
4. Goronzy J.J., and Weyand C.M. Thymic function and peripheral T-cell homeostasis in rheumatoid arthritis. Trends Immunol 22 (2001) 251-255
5. Corrigall V.M., and Panayi G.S. Autoantigens and immune pathways in rheumatoid arthritis. Crit Rev Immunol 22 (2002) 281-293
6. Doyle H.A., and Mamula M.J. Post-translational protein modifications in antigen recognition and autoimmunity. Trends Immunol 22 (2001) 443-449
7. Rudd P.M., Elliott T., Cresswell P., et al. Glycosylation and the immune system. Science 291 (2001) 2370-2376
8. van Gaalen F.A., van Aken J., Huizinga T.W., et al. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum 50 (2004) 2113-2121
9. Masson-Bessiere C., Sebbag M., Girbal-Neuhauser E., et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol 166 (2001) 4177-4184
10. Backlund J., Carlsen S., Hoger T., et al. Predominant selection of T cells specific for the glycosylated collagen type II epitope (263-270) in humanized transgenic mice and in rheumatoid arthritis. Proc Natl Acad Sci U S A 99 (2002) 9960-9965
11. Falgarone G., Jaen O., Boissier M.C., et al. Dendritic cells, lymphocytes, rheumatoid inflammation. Rev Rheum 72 (2005) 297-302
12. Weyand C.M., Goronzy J.J., Takemura S., et al. Cell-cell interactions in synovitis. Interactions between T cells and B cells in rheumatoid arthritis. Arthritis Res 2 (2000) 457-463
13. Jaen O., Rullé S., Bessis N., et al. Dendritic cells modulated by innate immunity improve collagen-induced arthritis and induce Tregs in vivo. Immunology 126 (2009) 35-44
14. Page G., Lebecque S., and Miossec P. Anatomic localization of immature and mature dendritic cells in an ectopic lymphoid organ: correlation with selective chemokine expression in rheumatoid synovium. J Immunol 168 (2002) 5333-5341
15. Feldmann M., Brennan F.M., and Maini R.N. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14 (1996) 397-440
16. Boissier M.C., Assier E., Falgarone G., et al. Shifting the imbalance from Th1/Th2 to Th17/treg: the changing rheumatoid arthritis paradigm. Joint Bone Spine 75 (2008) 373-375
17. Steinman R.M., Hawiger D., Liu K., et al. Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann N Y Acad Sci 987 (2003) 15-25
18. Falgarone G., Jaen O., and Boissier M.C. Role for innate immunity in rheumatoid arthritis. Joint Bone Spine 72 (2005) 17-25
19. Sakaguchi S., Sakaguchi N., Asano M., et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155 (1995) 1151-1164
20. + T cells from the target organ of patients with rheumatoid arthritis. Eur J Immunol 33 (2003) 215-223
21. Ehrenstein M.R., Evans J.G., Singh A., et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 200 (2004) 277-285
22. Schraven B., and Kalinke U. CD28 superagonists: what makes the difference in humans?. Immunity 28 (2008) 591-595
23. Boissier M., Assier E., Biton J., et al. T-REG and rheumatoid arthritis. Joint Bone Spine 76 (2009) 10-14
24. Ndejembi M.P., Teijaro J.R., Patke D.S., et al. Control of memory CD4 T cell recall by the CD28/B7 costimulatory pathway. J Immunol 177 (2006) 7698-7706
25. Davis P.M., Nadler S.G., Stetsko D.K., et al. Abatacept modulates human dendritic cell-stimulated T-cell proliferation and effector function independent of IDO induction. Clin Immunol 126 (2008) 38-47
26. Buch M., Boyle D., Saleem B., et al. The selective co-stimulation modulator abatacept decreases synovial inflammation and expression of pro-inflammatory cytokines in patients with rheumatoid arthritis. Arthritis Rheum 52S (2005) 446
27. Kliwinski C., Kukral D., Postelnek J., et al. Prophylactic administration of abatacept prevents disease and bone destruction in a rat model of collagen-induced arthritis. J Autoimmun 25 (2005) 165-171
28. Moreland L.W., Alten R., Van den Bosch F., et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 46 (2002) 1470-1479
29. Kremer J.M., Westhovens R., Leon M., et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349 (2003) 1907-1915
30. Kremer J.M., Dougados M., Emery P., et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52 (2005) 2263-2271
31. Genovese M.C., Schiff M., Luggen M., et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 67 (2008) 547-554
32. Kremer J.M., Genant H.K., Moreland L.W., et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 144 (2006) 865-876
33. Genant H., Peterfy C., Westhovens R., et al. Abatacept provides an increasing degree of inhibition of structural damage progression through 3 years in patients with RA and an inadequate response to methotrexate who remain on treatment. Ann Rheum Dis 67S (2008) 193
34. Ethgen O., and Koncz T. Modelling the sustainability of the DAS28 reduction with abatacept versus rituximab for rheumatoid arthritis patients with inadequate response to anti-TNF therapy. Ann Rheum Dis 67S (2008) 191
35. Dougados M., Schmidely N., Lafosse C., et al. Achievement of sustained LDAS predicts the absence of structural damage progression in patients with RA: Insights from the abatacept database. Ann Rheum Dis 67S (2008) 190
36. Weinblatt M., Combe B., Covucci A., et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 54 (2006) 2807-2816
37. Nogid A., and Pham D.Q. Role of abatacept in the management of rheumatoid arthritis. Clin Ther 28 (2006) 1764-1778
38. Tay L., Leon F., Vratsanos G., et al. Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects. Arthritis Res Ther 9 (2007) R38
39. Smitten A.L., Simon T.A., Hochberg M.C., et al. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 10 (2008) R45
40. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 (2006) 2275-2285